A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation

Cancer Prevention Research

Volumn 3, Issue 7, 2010, Pages 818-828

  Wu, Yongsheng ^a,b   Feng, Xiaoling ^b   Jin, Yucui ^a,b   Wu, Zhaojia ^a   Hankey, William ^b   Paisie, Carolyn ^b   Li, Lei ^a,b   Liu, Fengjuan ^a   Barsky, Sanford H ^b   Zhang, Weiwei ^a   Ganju, Ramesh ^b   Zou, Xianghong ^a,b  

^a CAPITAL NORMAL UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ATM PROTEIN; CELL DIVISION CYCLE 25A PHOSPHATASE; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 2; PHOSPHATASE; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INDUCTION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CDC25 PHOSPHATASES; CELL LINE; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION;

EID: 77954708496     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0213     Document Type: Article

References (50)

1. Seymour JD, Calle EE, Flagg EW, Coates RJ, Ford ES, Thun MJ. Diet Quality Index as a predictor of short-term mortality in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Am J Epidemiol 2003;157:980-8.
2. Feldman EB. Dietary intervention and chemoprevention-1992 perspective. Prev Med 1993;22:661-6.
3. Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007;55:224-36.
4. Naik R, Nixon S, Lopes A, Godfrey K, Hatem MH, Monaghan JM. A randomized phase II trial of indole-3-carbinol in the treatment of vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2006;16: 786-90.
5. Zhang J, Hsu BAJ, Kinseth BAM, Bjeldanes LF, Firestone GL. Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer 2003;98:2511-20.
6. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005;4:1201-15.
7. Cram EJ, Liu BD, Bjeldanes LF, Firestone GL. Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter. J Biol Chem 2001;276: 22332-40.
8. Rogan EG. The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo 2006;20:221-8.
9. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL. The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci U S A 2008;105:19750-5.
10. Brew CT, Aronchik I, Hsu JC, et al. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. Int J Cancer 2006;118:857-68.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
12. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-800. (Pubitemid 35334563)
13. Chen MS, Ryan CE, Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 2003;23:7488-97.
14. Galaktionov K, Beach D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991;67:1181-94.
15. Jinno S, Suto K, Nagata A, et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 1994;13:1549-56.
16. Galaktionov K, Lee AK, Eckstein J, et al. CDC25 phosphatases as potential human oncogenes. Science 1995;269:1575-7.
17. Gasparotto D, Maestro R, Piccinin S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res 1997;57:2366-8.
18. Wu W, Fan YH, Kemp BL, Walsh G, Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 1998;58:4082-5.
19. Cangi MG, Cukor B, Soung P, et al. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 2000;106:753-61.
20. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007;7: 495-507.
21. Chiu YT, Han HY, Leung SC, et al. CDC25A functions as a novel Ar corepressor in prostate cancer cells. J Mol Biol 2009;385:446-56.
22. Mailand N, Falck J, Lukas C, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000;288:1425-9.
23. Busino L, Donzelli M, Chiesa M, et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature 2003; 426:87-91.
24. Ray D, Terao Y, Nimbalkar D, et al. Transforming growth factor β facilitates β-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 2005;25:3338-47.
25. Jin J, Shirogane T, Xu L, et al. SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003; 17:3062-74.
26. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATMChk2-25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7.
27. Lazo JS, Wipf P. Is Cdc25 a druggable target? Anticancer Agents Med Chem 2008;8:837-42.
28. Brezak MC, Kasprzyk PG, Galcera MO, Lavergne O, Prevost GP. CDC25 inhibitors as anticancer agents are moving forward. Anticancer Agents Med Chem 2008;8:857-62.
29. Rudolph J. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nat Rev Cancer 2007;7:202-11.
30. Hillman GG, Wang Y, Kucuk O, et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004;3:1271-9.
31. Gunther EJ, Belka GK, Wertheim GB, et al. A novel doxycyclineinducible system for the transgenic analysis of mammary gland biology. FASEB J 2002;16:283-92.
32. Rahman KM, Sarkar FH, Banerjee S, et al. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol Cancer Ther 2006;5:2747-56.
33. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001;20:2927-36.
34. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18:2699-711.
35. Sebastian B, Kakizuka A, Hunter T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci U S A 1993;90:3521-4.
36. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004;11:1043-51.
37. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. Dual mode of degradation of Cdc25A phosphatase. EMBO J 2002;21:4875-84.
38. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
39. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 2000;97:10389-94.
40. Sharma S, Stutzman JD, Kelloff GJ, Steele VE. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 1994;54:5848-55.
41. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
42. Barbacid M, Ortega S, Sotillo R, et al. Cell cycle and cancer: genetic analysis of the role of cyclin-dependent kinases. Cold Spring Harb Symp Quant Biol 2005;70:233-40.
43. Sung WS, Lee DG. The candidacidal activity of indole-3-carbinol that binds with DNA. IUBMB Life 2007;59:408-12.
44. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-82
45. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004;64:2390-6.
46. Kang T, Wei Y, Honaker Y, et al. GSK-3β targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3β inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008;13: 36-47.
47. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008;68:7466-74.
48. Ding XL, Husseman J, Tomashevski A, Nochlin D, Jin LW, Vincent I. The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer's disease. Am J Pathol 2000;157:1983-90.
49. Fuhrmann G, Leisser C, Rosenberger G, et al. Cdc25A phosphatase suppresses apoptosis induced by serum deprivation. Oncogene 2001;20:4542-53.
50. Zou X, Tsutsui T, Ray D, et al. The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol Cell Biol 2001;21:4818-28.